Advertisements

Stugeron Forte

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Stugeron Forte

Quick Facts

Property Description
Active ingredient Cinnarizine (INN)
Form Oral tablet
Pharmacological class Antivertiginous agent, Calcium channel blocker, H1 Antagonist
Common use Management of vestibular disorders (balance problems)
Origin Synthetic organic small molecule (Piperazine derivative)

What Type of Medicine is Stugeron Forte?

Stugeron Forte is an oral tablet preparation whose active component is Cinnarizine, an agent used for its anti-vertigo properties. It is classified as an antivertiginous agent within the pharmaceutical system and is distinguished by its dual pharmacological identity. Cinnarizine operates as both a first-generation Histamine H1 receptor antagonist and a non-selective calcium channel blocker. This unique combination of actions positions it distinctly from medications that only target the H1 receptor.

Cinnarizine: Composition and General Purpose

The compound Cinnarizine is a synthetic small molecule derived from the piperazine family. As a single-ingredient product, it delivers a specialized therapeutic benefit: stabilizing the body's perception of motion. Its primary purpose is to act as a focused anti-motion sickness agent for individuals experiencing motion sensitivity, and as an antivertiginous agent for patients dealing with inner ear disturbances.

The mechanism by which it acts as a calcium channel blocker relates to microcirculation and vestibular suppression. This effect ensures the medication is fundamentally aimed at counteracting the sensation of spinning or unsteadiness. The "Forte" designation of this specific oral preparation indicates a higher concentration of Cinnarizine compared to the standard tablet, defining it as a variation in strength, not in therapeutic action.

Advertisements

What side effects are possible with Stugeron Forte?

Possible Side Effects and Safety Information

This section describes the adverse reactions and safety characteristics of Cinnarizine as formally documented in regulatory prescribing information.

Frequency-Classified Adverse Reactions

Adverse reactions are classified based on the frequency observed in clinical use:

Classification Examples of Documented Effects
Common (≥ 1/100 to < 1/10) Somnolence (drowsiness), Nausea
Uncommon (≥ 1/1,000 to < 1/100) Vomiting, Dyspepsia, Fatigue, Hyperhidrosis
Frequency Not Known Extrapyramidal Disorder, Cholestatic Jaundice, Lichen Planus

Serious Reactions and Special Safety Considerations

Documented serious adverse reactions with an unknown frequency include Extrapyramidal Symptoms (such as Parkinsonism and Tremor) and Cholestatic Jaundice (a liver-related condition). The regulatory profile notes that these serious neurological effects are observed more frequently in older adults during prolonged therapy.

Time-related patterns specify that somnolence may be more noticeable at the start of treatment.

Safety notes for specific populations include that patients with Parkinson's Disease should only use the medicine if the therapeutic benefits are considered to outweigh the risk of aggravating the condition. Use during pregnancy and lactation is generally not advised because safety data has not been fully established. Furthermore, the label states that use should be avoided in patients with a history of Porphyria.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with the active ingredient Cinnarizine (Stugeron Forte) is a serious event that requires immediate medical attention. Documented overdoses have involved ingestion levels ranging from 90 mg up to 2,250 mg.


Documented Manifestations and Severe Outcomes

Official regulatory information describes a wide range of manifestations, primarily affecting the Central Nervous System (CNS). These include a spectrum of alterations in consciousness, ranging from somnolence and profound CNS depression to stupor and coma. Other documented signs include vomiting, extrapyramidal symptoms, hypotonia, and potentially seizures.

Of critical concern, the regulatory profile notes that deaths have been reported following single-drug and polydrug overdoses. Severe outcomes also include the potential for cardiorespiratory collapse.


Required Emergency Actions

The most important regulatory instruction is to seek immediate medical attention and to contact a poison control center for management recommendations. Treatment is strictly symptomatic and supportive care, as no specific antidote is known for cinnarizine overdose. Procedural measures such as gastric lavage and the administration of activated charcoal may be utilized to reduce absorption.

Pediatric Overdose Consideration

Infants and children are a particularly vulnerable population, with regulatory documents citing an increased severity of overdose symptoms, including a higher risk of seizures and distinctive antimuscarinic effects. These patients require specialized hospital monitoring and observation in a health care facility due to the potential for severe neurological complications.

Advertisements

Therapeutic Uses of Stugeron Forte

Stugeron Forte contains cinnarizine, a medication used for the symptomatic management of specific conditions related to balance and motion. The medication is primarily employed for support in scenarios involving vestibular disorders (inner ear issues) and for helping lessen symptoms of certain types of motion sickness. The intended benefit is the relief of uncomfortable symptoms such as vertigo, dizziness, tinnitus (ringing in the ears), and associated nausea or vomiting.

The specific therapeutic domains of this medicine include the symptomatic support of conditions like Ménière’s disease and other forms of labyrinthine disorders. It is also indicated for use in motion sickness (kinetosis). Cinnarizine is a treatment option that may assist in the management of these symptoms.

Quick Fact: Support for Vertigo and Dizziness

The indications for this medicine include support for symptoms of vertigo, tinnitus, nausea, and vomiting associated with Ménière’s disease, other labyrinthine disorders, and in cases of motion sickness.

Advertisements

Eligibility and Restrictions for Use

Who can and cannot use Stugeron Forte?

Eligibility for Stugeron Forte (Cinnarizine) is strictly governed by regulatory labeling, defining populations that must not use the medicine and those requiring special caution.


The medication is contraindicated and must not be used by individuals with a known hypersensitivity to cinnarizine or any of its excipients. It is also absolutely prohibited for patients diagnosed with Porphyria, a specific rare hereditary condition.

Age-related rules state that use is generally not recommended for children under 5 years but is considered acceptable for individuals aged 5 years and over.

Specific medical conditions necessitate restricted use. Patients with Parkinson's disease are only permitted to use Stugeron Forte if the treatment benefit clearly outweighs the risk of aggravating their existing condition. Use requires care in individuals with hepatic or renal insufficiency, and caution is advised in the elderly during prolonged therapy. Due to lack of established safety data, the medicine is not recommended for use in women who are pregnant or breastfeeding.

Advertisements

What should I know about interactions with other medicines?

The official product information documents specific interactions with other substance classes, primarily concerning the potential for enhanced sedation and interference with diagnostic procedures.

Other Medicinal Products and Alcohol

The simultaneous use of the active substance in Stugeron Forte (cinnarizine) with other medications that cause central nervous system (CNS) depression requires caution. Concomitant administration of the following categories of substances may potentiate the sedative effects of either this product or the co-administered agents:

  • Central Nervous System (CNS) Depressants (including other medicines that cause drowsiness or somnolence)
  • Tricyclic Antidepressants
  • Alcohol

The potential for increased sedation is a relevant clinical consideration, especially as cinnarizine may cause somnolence, particularly when treatment is initiated. It is documented that alcoholic beverages should be avoided during treatment due to the potential for enhanced sedative effects.

Diagnostic Interference

The product's antihistamine effect has a documented impact on certain medical tests. Specifically, the use of cinnarizine may prevent a positive reaction to dermal reactivity indicators, leading to false-negative results in skin tests for allergies. It is officially stated that the product may interfere with these results if it is administered up to four days prior to the skin testing procedure.

Advertisements

Mechanism of Action

Pharmacodynamic Mechanism of Cinnarizine

Cinnarizine functions through a dual pharmacodynamic mechanism involving selective H1 histamine receptor antagonism and calcium channel blockade. The molecule engages in competitive binding at the peripheral and central H1 receptor sites. This interaction modulates the central processing of neural signals associated with motion and equilibrium.

Simultaneously, cinnarizine acts as a selective calcium channel blocker, inhibiting the influx of extracellular calcium ions ( Ca^2+) into vascular smooth muscle cells. This Ca^2+ channel modulation promotes the vasodilation of small blood vessels, particularly affecting the microcirculation within the brain and the labyrinthine vessels of the inner ear. The combined effect of H1 antagonism and reduced cellular Ca^2+ flux diminishes the overall excitability of the vestibular neuro-epithelium, resulting in a modulation of afferent signal transmission from the vestibular system.

Advertisements

Dosage and Administration Information

Administration Scope

The administration of Stugeron Forte, which contains the active ingredient Cinnarizine, follows standardized instructions for use. The medicine is formulated for oral administration as a tablet.

Category Instruction for Use
Route of administration Oral administration only.
Dosing schedule (Adults) Maximum recommended dose should not exceed 225 mg daily.
Maintenance: Typically 25 mg three times daily, or 75 mg once a day (for the Forte strength). Dosage may be increased progressively as appropriate.
Motion Sickness Prophylaxis Initial dose of 25 mg taken half an hour before travel; subsequent doses may be repeated every 6 to 8 hours during the journey.
Timing in relation to meals Should preferably be taken after meals (postprandial) to help diminish gastric irritation.
Age-group administration rules Children 8 to 12 years typically receive half the adult dose for both maintenance and prophylaxis.
Missed-dose rules If a dose is forgotten, the patient should skip the missed dose and resume the usual schedule; an interval of at least 8 hours must be maintained between doses.

Instruction Classifications (High-Level)

Classification Parameter
Administration method type Oral (Tablet ingestion)
Frequency pattern Daily (TID or OD) for maintenance; Intermittent (As-needed) for prophylaxis.
Use-context constraints Food-dependent timing; Purpose-dependent frequency.

Resulting Procedural Structure

Standardized step sequence:

  • Take the prescribed dose after a meal.
  • Administer the medicine in accordance with the specified frequency: either three times daily, once daily, or intermittently for motion sickness.
  • Ingestion may involve swallowing whole, chewing, or sucking the tablet, depending on the labeled formulation instructions.

Connection to the overall use protocol (2–4 sentences): The administration protocol establishes a structural framework that is built upon a non-parenteral, oral delivery system. This framework indicates that the total daily dosage and frequency are contingent upon the intended application (chronic versus acute) and includes an instruction to administer the dose postprandially to ensure consistent use.

Advertisements

Recent Clinical Evidence

Stugeron Forte: Recent Clinical Evidence

This section summarizes findings from clinical studies regarding the active ingredient in Stugeron Forte, cinnarizine, which is a medication primarily investigated for vestibular disorders and motion sickness. This information is a summary of research and is not a substitute for professional medical advice.


Evaluation in Vestibular Disorders

Clinical trials, including randomized controlled trials, have examined the use of cinnarizine for symptoms associated with conditions such as Meniere's disease and various forms of vertigo. Research has explored the drug’s relationship with specific inflammatory pathways and its known calcium channel blocking properties, which are thought to help stabilize the inner ear's sensory system.

  • Symptom Assessment: Studies assessed the drug's influence on vertigo symptoms, often using validated scoring systems. Findings generally suggested an improvement in symptom intensity over a defined treatment period compared to baseline measurements.
  • Combination Research: Cinnarizine has frequently been studied in a fixed-dose combination with other medications (like dimenhydrinate) for treating vertigo. These combination studies often reported a greater reduction in vertigo symptoms compared to using either monotherapy alone, based on specific outcome scales.

Safety Profile in Research

Safety evaluations from clinical trials, which included subjects treated with cinnarizine doses up to 225 mg/day, provide data on the drug's tolerability.

Common Adverse Events (Reported at ge1% incidence in trials) Notes on Safety
Somnolence (Drowsiness) Contraindications: The use of cinnarizine is generally cautioned against in patients with Parkinson's disease, as it may aggravate motor function.
Weight increased Interaction Risk: Due to its effects, caution is advised when co-administering with alcohol, central nervous system (CNS) depressants, or tricyclic antidepressants.

Long-term data from observational studies further monitored the safety profile over periods such as 12 months. Based on the evidence reviewed, the drug was generally well received by participants in controlled clinical settings.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Stugeron Forte (FAQ)

Q: Is Stugeron Forte the same as regular Stugeron, and what's the difference?

A: Stugeron Forte is a specific preparation that contains a higher strength of the active ingredient, Cinnarizine, compared to the standard Stugeron tablet. The 'Forte' designation is used by the manufacturer to distinguish this formulation, which is intended to allow for specific prescribed dosing schedules, such as maintenance dosing.


Q: How long does the effect of Stugeron Forte typically last?

A: Official product information suggests a half-life, which describes the time it takes for half of the substance to leave the body, can vary significantly among individuals. For motion sickness prevention, the drug is typically administered at intervals specified in the dosing schedule.


Q: What over-the-counter pain relievers interact with Stugeron Forte?

A: Regulatory documents do not list specific brand names of over-the-counter pain relievers. Official warnings highlight the need for caution when co-administering with medicines that cause Central Nervous System (CNS) depression, as this combination may increase the sedative effects of Cinnarizine.


Q: Is it safe to take Stugeron Forte with commonly prescribed blood pressure medications?

A: Cinnarizine is known to act as a calcium channel blocker and can have a blood vessel-widening effect. Prescribing information advises caution, particularly when using higher doses in patients who already have low blood pressure, as the medication could potentially decrease blood pressure further. Patients taking blood pressure medication are advised to consult with a healthcare professional regarding potential effects.


Q: Can Stugeron Forte be crushed or dissolved for easier swallowing?

A: Administration instructions for Cinnarizine formulations commonly indicate that tablets may be swallowed whole, chewed, or sucked. However, crushing is generally not specified as an approved method for this formulation, and patients should follow the exact instructions provided with their specific product.


Q: Does food affect how well Stugeron Forte is absorbed?

A: According to the official product information, the medicine should preferably be taken after meals. This recommendation is based on helping to diminish the potential for stomach upset or gastric irritation.


Q: What are the common foods or beverages to avoid while taking Stugeron Forte?

A: Official regulatory warnings specifically advise avoiding alcoholic beverages during treatment. This is due to the potential for alcohol to enhance the sedative effects of Cinnarizine. No specific food items are mentioned in official regulatory documents as being strictly prohibited.


Q: Are there any long-term studies on the safety of Stugeron Forte?

A: Long-term data from observational studies are used by regulatory bodies to monitor the safety profile of Cinnarizine, particularly in older patients receiving prolonged therapy. The drug is commonly intended for short-term use in acute conditions.


Q: What is the difference between Cinnarizine and Stugeron Forte?

A: Cinnarizine is the active ingredient, which is the chemical compound that provides the therapeutic benefit. Stugeron Forte is a specific brand name product that contains Cinnarizine in a higher-strength formulation.


Q: Does Stugeron Forte help with general motion sickness?

A: Yes, official therapeutic indications state that Cinnarizine is used for both the prevention and treatment of symptoms related to motion sickness. It is also indicated for managing balance issues related to inner ear disorders.


Q: Can Stugeron Forte be used for balance issues not related to travel?

A: Yes, regulatory documents indicate that the medicine is used for the symptomatic treatment of various vestibular disorders. These conditions, such as vertigo and dizziness associated with Ménière's disease, are balance issues related to the inner ear that are often unrelated to travel.


Q: Can Stugeron Forte affect my ability to concentrate?

A: Because Cinnarizine may cause somnolence (drowsiness), especially when treatment is first started, official prescribing information advises caution. Drowsiness may affect an individual’s ability to concentrate, drive, or operate heavy machinery.


Q: Are there different strengths of Stugeron Forte available?

A: The name 'Stugeron Forte' itself refers to a specific, higher strength of Cinnarizine. However, other strengths of the same active ingredient may be available under different brand names or as the standard Stugeron product.


Q: Is it okay to take Stugeron Forte on an empty stomach?

A: Official guidance indicates that taking the medicine after a meal is the preferred method of administration. This is because administering it post-meal is recommended to help minimize the risk of gastric irritation and stomach upset.


Q: Is it normal to feel a dry mouth when taking this medication?

A: Dry mouth is listed in the official prescribing information as a documented adverse effect associated with the use of Cinnarizine.


Q: Are there genetic factors that influence how Stugeron Forte works for someone?

A: Official information mentions that Cinnarizine is extensively processed in the body by the CYP2D6 enzyme system. Because the activity of this enzyme can vary considerably from person to person, this variation suggests one factor that may contribute to differences in how individuals process the medication.


Q: Has Stugeron Forte been approved by major regulatory bodies globally?

A: Cinnarizine is approved and widely used under different brand names in many regions, including the UK and Europe, where its use is governed by bodies like the MHRA and EMA. Cinnarizine is not generally approved for sale in the United States by the FDA.


Q: Why might a person's response to Stugeron Forte be different from someone else's?

A: Differences in how individuals process Cinnarizine can lead to variations in effectiveness and side effects. Regulatory information highlights that the body’s metabolism of the drug, which is handled by the CYP2D6 enzyme, shows considerable variation between different people.


Q: Can Stugeron Forte cause problems with vision?

A: Although generally rare, some reports of adverse reactions, particularly when Cinnarizine is used in combination with other substances, have included impaired vision. Additionally, anticholinergic properties of the drug can sometimes affect the eyes, and caution is advised.


Q: What is the purpose of the 'Forte' designation in the drug name?

A: The purpose of the 'Forte' designation is to clearly distinguish this product as the version that contains a higher amount of the active ingredient, Cinnarizine, which is often used to accommodate specific treatment plans, such as once-daily maintenance dosing.

Advertisements

How should Stugeron Forte be stored and disposed of?

How to Store and Dispose of Stugeron Forte

The storage and disposal of Stugeron Forte (cinnarizine) tablets are defined by regulatory requirements to ensure product stability and safe environmental handling.

Storage Requirements

The medicine must be stored at temperatures below 30°C and must be protected from both light and moisture. It is required to keep the tablets in their original container or package and to maintain the container tightly closed when not in use. For safety, the product must be stored out of the sight and reach of children.

Disposal Instructions

Stugeron Forte must not be used after the expiry date shown on the packaging. Unused or expired tablets must not be thrown away via wastewater or household waste. Official procedure requires patients to ask a pharmacist how to properly dispose of the medicine according to local pharmaceutical waste management requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Stugeron Forte found in:

A-Z Index: